Granules India Q3FY26 Results: Revenue ₹8,953 Cr, Profit ₹1,116 Cr
Granules India reported Q3FY26 revenue of ₹8,953 crore and profit of ₹1,116 crore. Consolidated revenue stood at ₹13,879 crore with profit at ₹1,502 crore. The company acquired Granules Pharmaceuticals GmbH and approved capital raising of ₹14,625 crore via warrants and ₹3,000 crore via equity.
The financial results, along with significant strategic actions like acquisitions and substantial capital raising plans, are expected to have a material impact on the company's future performance and market position.
The company reported positive financial results with increased revenue and profit for the quarter and nine-month period. The acquisition and capital raising plans indicate strategic growth initiatives.
Granules India Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company reported a total revenue from operations of ₹8,953.18 crore for the quarter, a slight increase from the previous quarter. Profit after tax for the quarter stood at ₹1,115.82 crore.
For the nine-month period ended December 31, 2025, Granules India reported a total revenue from operations of ₹25,971.39 crore and a profit after tax of ₹3,016.80 crore. The company also disclosed an exceptional item for the nine months, amounting to ₹121.60 million (₹12.16 crore) in transaction costs related to the acquisition of Senn Chemicals AG.
The consolidated financial results for the same period showed a total revenue from operations of ₹13,879.40 crore for the quarter and ₹39,065.89 crore for the nine months. Consolidated profit after tax for the quarter was ₹1,502.11 crore, and for the nine months, it was ₹3,934.53 crore. The consolidated results also included exceptional items amounting to ₹259.11 million (₹25.91 crore) for the nine months, related to acquisition costs and litigation settlements.
The company highlighted the acquisition of M/s Granules Pharmaceuticals GmbH in Germany on November 20, 2025, and the incorporation of a new subsidiary, Granules Pharmaceuticals Canada, Inc., in Canada on November 26, 2025. Additionally, the Board of Directors and shareholders approved capital-raising measures, including the issuance of convertible warrants aggregating up to ₹14,625 crore and equity shares aggregating up to ₹3,000 crore, subject to regulatory approvals.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.